TransMedics and Mercedes-Benz partner on organ transport network in Italy

ANDOVER, Mass. - TransMedics Group, Inc. (NASDAQ:TMDX), a medical technology company with a market capitalization of $4.17 billion and impressive year-to-date stock gains of 96%, announced today a strategic collaboration with Mercedes-Benz Group AG to deploy a fleet of purpose-built Mercedes-Benz V-Class vehicles dedicated to organ transportation across Italy. According to InvestingPro data, the company maintains excellent financial health with a "GREAT" overall score, supporting its expansion initiatives.

The initiative will establish four National Organ Care System (NOP) hubs in Milan, Rome, Padua, and Bari, expected to launch before the end of 2025. Each hub will be equipped with TransMedics’ Organ Care System (OCS) technology for lungs, hearts, and livers, and staffed by clinical perfusionists providing 24/7 support. The company’s strong liquidity position, with current assets significantly exceeding short-term obligations, positions it well for this expansion. For deeper insights into TransMedics’ financial strength and growth potential, investors can access comprehensive analysis through InvestingPro’s detailed research reports.

The specially equipped vehicles will meet safety specifications for transplant logistics, providing secure transport for organs, physicians, and equipment. The Italian National Command Center will operate from TransMedics’ hub in Santa Giulia, Milan.

"Our NOP initiative in Italy is a crucial first step towards expanding global access to our life-saving OCS technology to patients in need," said Waleed Hassanein, President and CEO of TransMedics, according to the press release.

Dario Albano, Managing Director of Mercedes-Benz Vans Italia, stated that the company’s vehicles are "engineered for professional, mission-critical operations."

The collaboration supports TransMedics’ strategy to replicate its U.S. NOP model in Europe by building a dedicated logistics network that complements its organ perfusion technology. The OCS platform is designed to maintain donor organs in a functioning state outside the body by perfusing them with warm, oxygenated blood.

TransMedics management will be available for interviews during the upcoming Italian Society for Organ and Tissue Transplantation Congress in Milan.

The announcement was made in a company press release issued Monday.

In other recent news, TransMedics Group reported its financial results for the second quarter of 2025, surpassing market expectations with an earnings per share of $0.92, more than doubling the forecast of $0.45. The company also exceeded revenue projections, bringing in $157.4 million compared to the anticipated $146.74 million. In regulatory developments, the U.S. Food and Drug Administration granted conditional approval for TransMedics’ Investigational Device Exemption, allowing the company to proceed with its Next-Generation OCS ENHANCE Heart trial. This trial aims to advance heart preservation for transplants and is expected to be the largest of its kind globally.

Meanwhile, Evercore ISI initiated coverage on TransMedics with an Outperform rating, citing growth potential and setting a price target of $155.00. Stifel, on the other hand, began coverage with a Hold rating and a $115.00 price target, based on mixed survey results from U.S. transplant surgeons regarding the company’s organ care system technology. TD Cowen reaffirmed its Buy rating on the company, highlighting TransMedics’ strong position in the organ transplant market. These developments reflect varied analyst perspectives on the company’s market performance and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.